Background-Both the effect of the mutation and the pathogenesis of Huntington's disease are unknown and a lack of biological markers for the natural history of the disease impedes the evaluation of novel therapeutic approaches. Methods-Proton magnetic resonance spectroscopy was carried out on a frontal region of the cortex in 17 patients with clinically overt Huntington's disease and four asymptomatic gene carriers. Results-Eight of 17 (47%) clinically affected patients with Huntington's disease and each of the asymptomatic carriers had lactate peaks in the frontal cortex which were not present in controls. The N-acetyl-aspartate/choline (NAA/Ch) ratio was significantly reduced in the symptomatic patients indicating the presence of neuronal loss. The reduction was related to the clinical severity of the disease and was absent in the asymptomatic carriers. Conclusion-The finding of lactate peaks supports the hypothesis that disturbed cerebral energy metabolism contributes to the pathogenesis of Huntington's disease. (y Neurol Neurosurg Psychiatry 1997;62:27-30) 
After an increased number of CAG repeats was shown to be the genetic defect in Huntington's disease,' efforts were concentrated on the functional consequences of the mutation, pathogenesis of the disease, and future neuroprotective strategies. There is evidence that impairment of production of chemical energy significantly contributes to the pathogenesis of striatal lesions in Huntington's disease,25 in particular, because inhibition of cerebral oxidative phosphorylation results in a pattern of vulnerability closely resembling the disease.68 As these lesions can be attenuated or prevented by antagonists to glutamate receptors, it has been postulated that the mechanism of "weak" excitotoxicity is a major contributing pathogenetic factor.9 Such a hypothesis is supported by PET studies, which show reduced glucose and oxygen metabolism of the basal ganglia and cortex in patients with Huntington's disease. [10] [11] [12] We have studied the frontal cortex for several reasons. Firstly, there is neuropathological evidence that this region is involved in Huntington's disease"3 but precise correlations with the development of the clinical features are as yet lacking. Secondly, recent PET studies have convincingly showed reduced glucose metabolism in various stages of clinical disease including mild and severe forms." 12 14 Finally, neuropsychological deficits have also been reported in Huntington's disease, which have been attributed to frontal lobe dysfunction. '5 16 For these reasons, we carried out lactate measurements and determined the N-acetylaspartate/choline (NAA/Ch) ratio by proton magnetic spectroscopy in a selected volume of the frontal lobe.
Subjects and methods
We examined 26 patients with a definitive molecular genetic diagnosis of Huntington's disease; in five of these patients the spectra could not be evaluated as choreoathetotic movements impeded the acquisition of spectroscopic data. These patients were excluded from the study. Each patient was given a clinical examination by a neurologist (HM) and subsequently the severity of the condition was defined from the Shoulson score'7 and the motor score of the United Huntington's Disease Rating Scale (UHDRS 
Results
The Ch/Cr ratios did not show any significant differences between groups (group I 1-06 (0 06), group II 0 95 (0-13), group III 0 97 (0 07), group IV 0 94 (0 11), group V 1-07 (0-28)). We tried to relate the NAA/Ch ratiowhich is accepted to reflect the amount of the neuronal marker NAA22 to the clinical findings in our patients. Whereas these ratios were indistinguishable in asymptomatic gene carriers, mildly affected patients, and controls (group I 1-73 (0x41), group II 1-83 (0 29), group V 1-80 (0 37)) (fig 2) , they were decreased in group III (1 -41 (0 24)) and group IV patients (1-26 (0 23)). The differences between controls (group V) and groups III (P = 0-022) and IV (P = 0 008) were significant There was no significant relation between the reduction in NAA/Ch ratio and duration of the disease, age of the patients, and number of CAG repeats.
In the frontal cortex lactate peaks were present in eight of the 17 symptomatic patients and each of the four asymptomatic gene carriers but not in the controls (fig 3A-C Although it seemed that duration and severity of the disease and low NAA were broadly pre-Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe ofpatients with Huntington's disease 
